Trial protocols define how investigators watch for these events
Who is generally a candidate Adults 18 and older with a BMI of 30 or higher (obesity), or Adults with a BMI of 27 or higher plus at least one weight-related condition: type 2 diabetes, hypertension, dyslipidemia, or obstructive sleep apnea No disqualifying personal or family medical history (see below) Willing to attend an in-person evaluation and follow-up visits during titration Who we generally do not prescribe to Personal or family history of medullary thyroid carcinoma or MEN2 syndrome (multiple endocrine neoplasia type 2) History of pancreatitis Severe gastroparesis or other significant gastrointestinal motility disease Pregnancy , breastfeeding, or actively planning pregnancy An active eating disorder Known hypersensitivity to semaglutide, tirzepatide, or a formulation's inactive ingredients We also look at what else is driving your case before deciding a GLP-1 is the right tool
Neuroprotective effects of peroxisome proliferator-activated receptor alpha and gamma agonists in model of parkinsonism induced by intranigral 1-methyl-4-phenyl-1,2,3,6-tetrahyropyridine
The risk is dose-dependent, meaning higher doses carry higher risk, and it increases significantly above 450mg daily
Treatment with Fc-GLP-1 in mice fed a chow diet significantly increased Acta2 (encoding -SMA), Col1a1 , Tgfb and Mmp2 mRNAs (Fig
